Alani Capital

Alani Capital is a small, thesis-driven early-stage firm that operates at the unusual intersection of decentralized AI, climate technology, and healthcare. The combination is deliberate. The firm’s underlying view is that decentralized infrastructure, modern AI techniques, and the demands of a changing climate are remaking the substrate on which healthcare, energy, and computation are delivered, and that the most important companies of the next decade will operate across those boundaries. Alani is currently launching its Orange Fund II, which signals a continuation and expansion of that thesis with a fresh capital base. For founders building at unconventional intersections, Alani is one of the few early checks in the United States that takes the boundaries seriously.

The healthcare-specific thesis covers AI and ML in healthcare, tech-enabled care delivery, diagnostics, and digital health. Alani pays particular attention to companies that use modern AI techniques to change the cost structure of care delivery or diagnostics, and to companies whose architecture leverages decentralized data, decentralized compute, or other infrastructural choices that move beyond the centralized cloud model. The firm is comfortable with technical complexity and is willing to underwrite both AI and infrastructure risk when the team and thesis are credible. It tends to be skeptical of generic digital health products that lack a specific technical or structural insight, and it rewards founders who can articulate why their architecture choices matter for the long-term defensibility of the business.

The input data does not enumerate specific portfolio companies, so founders should request the current portfolio during initial conversations. The publicly observable pattern is a concentration on early-stage technical companies at the intersection of AI, decentralized infrastructure, climate, and healthcare. Founders should expect Alani to engage seriously with technical architecture and to ask detailed questions about how their company’s structural choices translate into commercial advantage. The firm is comfortable with companies that look unusual to mainstream healthcare investors.

Check sizes typically run below two hundred fifty thousand dollars at entry, which positions Alani as a participant in pre-seed and seed rounds rather than a lead for larger checks. Founders should plan their syndicate accordingly, treating Alani as a high-signal early addition that strengthens the cap table on technical and architectural credibility. Reserves are deployed selectively, and founders should not assume Alani will lead a Series A. The stage focus is firmly pre-seed and seed, with the launch of Orange Fund II potentially expanding the firm’s flexibility on check size over time.

Decision-making is concentrated in a small team, and the firm operates with the velocity of a focused early-stage shop. Founders should expect direct engagement with the partners and a process that values clarity of technical thought. Alani’s culture is thesis-driven, which means founders who come prepared to discuss the substance of their architectural and AI choices will find the conversation moves quickly to depth.

The right approach is a warm introduction from a technical founder in the Alani network, an AI or decentralized infrastructure operator, or a portfolio company. Cold outreach is read, particularly when the founder leads with a clear technical thesis and a credible team. Founders should arrive with a clear point of view on data, decentralization, and AI, and an honest read on what is genuinely novel about the company’s approach.

What founders should know is that Alani Capital is a fit for technically ambitious founders building at unconventional intersections of AI, decentralization, climate, and healthcare. Founders building conventional digital health products without a meaningful technical or architectural dimension will find a less natural fit. Founders working at the genuine frontier of how healthcare and computation intersect will find Alani one of the more thoughtful early-stage partners in that specific space.